INOTUZUMAB OZOGAMICIN IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA REFRACTORY TO RITUXIMAB AND CHEMOTHERAPY OR RADIOIMMUNOTHERAPY

被引：0
|
作者：
Goy, A. [1 ]
Leach, J. [2 ]
Tsai, M. [2 ]
Foran, J. [3 ]
Forero, A. [4 ]
Wagner-Johnston, N. [5 ]
Ehmann, C. [6 ]
Egyed, M. [7 ]
Ando, K. [8 ]
Hatake, K. [9 ]
Tobinai, K. [10 ]
Feldman, T. [1 ]
Vandendries, E. [11 ]
Volkert, A. [11 ]
Wang, S. L. [11 ]
Ogura, M. [12 ]
机构：
[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Pk Nicollet Frauenshah Canc Ctr, St Louis Pk, MN USA
[3] Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Hershey Med Ctr, Hershey, PA USA
[7] Kaposi Mor Teaching Hosp, Kaposvar, Hungary
[8] Tokai Univ Hosp, Isehara, Kanagawa, Japan
[9] Canc Inst Hosp, Tokyo, Japan
[10] Natl Canc Ctr, Tokyo, Japan
[11] Pfizer Inc, Cambridge, MA USA
[12] Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0793
引用
收藏
页码：324 / 324
页数：1
相关论文
共 50 条
  • [1] A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
    Goy, Andre
    Forero, Andres
    Wagner-Johnston, Nina
    Ehmann, W. Christopher
    Tsai, Michaela
    Hatake, Kiyohiko
    Ananthakrishnan, Revathi
    Volkert, Angela
    Vandendries, Erik
    Ogura, Michinori
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (04) : 571 - 581
  • [2] INOTUZUMAB OZOGAMICIN IN B-CELL NON-HODGKIN'S LYMPHOMA REFRACTORY TO RITUXIMAB plus CHEMOTHERAPY OR RADIOIMMUNOTHERAPY
    Ogura, M.
    Leach, J.
    Egyed, M.
    Ando, K.
    Hatake, K.
    Tobinai, K.
    Feldman, T.
    Hua, S.
    Volkert, A.
    Vandendries, E.
    Goy, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [3] Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease
    Visser, Otto J.
    Perk, Lars R.
    Zijlstra, Josee M.
    van Dongen, Guus A. M. S.
    Huijgens, Peter C.
    van de Loosdrecht, Arjan A.
    [J]. BIODRUGS, 2006, 20 (04) : 201 - 207
  • [4] Radioimmunotherapy for Indolent B-Cell Non-Hodgkin Lymphoma in Relapsed, Refractory and Transformed Disease
    Otto J. Visser
    Lars R. Perk
    Josée M. Zijlstra
    Guus A.M.S. van Dongen
    Peter C. Huijgens
    Arjan A. van de Loosdrecht
    [J]. BioDrugs, 2006, 20 : 201 - 207
  • [5] Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Ogura, Michinori
    Castaigne, Sylvie
    Fayad, Luis E.
    Jerkeman, Mats
    Radford, John
    Pezzutto, Antonio
    Bondarenko, Igor
    Stewart, Douglas A.
    Shnaidman, Michael
    Sullivan, Sharon
    Vandendries, Erik
    Tobinai, Kensei
    Ramchandren, Radhakrishnan
    Hamlin, Paul A.
    Gine, Eva
    Ando, Kiyoshi
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (04) : 583 - 586
  • [6] Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-Cell non-Hodgkin lymphoma
    Kahl, Brad
    Bartlett, Nancy L.
    Leonard, John P.
    Ganjoo, Kristen
    Williams, Michael E.
    Czuczman, Myron S.
    Robinson, K. Sue
    Joyce, Robin
    van der Jagt, Richard H.
    Cheson, Bruce D.
    [J]. BLOOD, 2007, 110 (11) : 406A - 407A
  • [7] Radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Witzig, Thomas E.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 655 - 668
  • [8] INOTUZUMAB OZOGAMICIN (INO, CMC-544) IN PTS WITH INDOLENT B-CELL NHL REFRACTORY TO RITUXIMAB (R), R PLUS CHEMOTHERAPY, OR RADIOIMMUNOTHERAPY (RIT)
    Goy, A.
    Leach, J.
    Ehmann, W. C.
    Egyed, M.
    Ando, K.
    Hatake, K.
    Tobinai, K.
    Feldman, T.
    Hua, S.
    Volkert, A.
    Vandendries, E.
    Ogura, M.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 105 - 105
  • [9] Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial
    Goy, Andre
    Leach, Joseph
    Ehmann, Christopher
    Ando, Kiyoshi
    Hatake, Kiyohiko
    Tobinai, Kensei
    Feldiman, Tatyana
    Hua, Steven
    Volkert, Angela D. G.
    Vandendries, Erik R.
    Ogura, Michinori
    [J]. BLOOD, 2010, 116 (21) : 192 - 193
  • [10] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    Witzig, TE
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S91 - S95
12345